#USA #Dallas #CAR-T #CellFE #T-Rest

CellFE Unveils Groundbreaking T-Rest Kit

In an exciting development for the field of cell therapy, CellFE, a pioneer in non-viral gene editing technology, has launched its innovative product, the T-Rest (Resting T Cell Kit). This first-in-class transfection media is designed to optimize the workflow for the manufacturing of resting (quiescent) T cells, which are crucial for developing effective CAR-T cell therapies. The official unveiling occurred at Advanced Therapies Week (ATW) 2025, held in Dallas, Texas from January 20-23.

A Revolutionary Approach to Cell Manufacturing

CellFE’s T-Rest Kit emerges as a game-changer in the realm of cell therapy manufacturing. The product supports a fully optimized gene editing process that utilizes resting T cells as the starting material. Traditionally, T cell therapies have faced challenges related to the safety and potency of the final products, often derived from activated T cells. In contrast, T-Rest offers a new paradigm, allowing manufacturers to develop therapies that are not only safer but also more potent.

Resting T cells are advantageous in this context because they can retain vital stem cell memory, which is essential for creating long-lasting CAR-T cells. This preservation of stem cell memory enhances the durability of CAR-T therapies, making them more effective in treating various cancers. Moreover, using non-dividing cells like resting T cells helps minimize the risk of chromosomal abnormalities, a significant concern in gene editing.

Supporting Data and Collaboration

To complement the launch, CellFE released an application note detailing the non-viral, non-electroporative workflows associated with the T-Rest Kit. This document showcases the latest data regarding CAR-T cell editing using resting T cells. CellFE emphasizes that the T-Rest Kit is designed to work seamlessly with their leading microfluidic gene delivery platform, the Infinity MTx™, providing a robust solution for engineering therapeutic cells.

Alla Zamarayeva, the CEO of CellFE, expressed her enthusiasm about the product launch, stating, “We are thrilled to introduce T-Rest - the first commercial product specifically designed for resting T cells. This innovation addresses the pressing durability and safety concerns that cell therapy manufacturers face today.”

Upcoming Events and Community Engagement

During the Advanced Therapies Week, CellFE set up Booth #752 to demonstrate the T-Rest Kit live and engage with attendees. They also announced an exciting initiative - the formation of a Non-Viral Cell Therapy Working Group, which will focus on advancing the community standards and practices around non-viral therapies. The working group’s kickoff event will take place at the conference, fostering collaboration among various stakeholders in the cell therapy industry.

For those attending ATW, CellFE is eager to facilitate discussions about the future impact of this working group on the evolving landscape of cell therapies. To learn more, interested parties can visit the exhibition booth or sign up for upcoming events through the CellFE website.

About CellFE

As a revolutionary force in microfluidics, CellFE is dedicated to transforming the development and manufacturing of life-saving cell therapies, making them more widely accessible to patients. With a special focus on T cell, hematopoietic stem cell (HSC), and induced pluripotent stem cell (iPSC)-based therapies, CellFE leverages microfluidics technology to overcome key market challenges, such as high manufacturing costs and lengthy production timelines. For further insights into their innovative solutions, visit CellFE's official website.